{
    "medicine_id": "1a6f70312f6d8dcd8864ad78011c692ed131c0a2",
    "platform_id": "DB13518",
    "metadata": {
        "name": "Gastrocote Chewable Tab 2 5 mg Suspension",
        "composition": "2 5 mg Alginic acid",
        "clinical_particulars": {
            "therapeutic_indications": "Indicated for the management of gastric reflux reflux oesophagitis hiatus hernia heartburn including heartburn of pregnancy and similar gastric distress F46",
            "contraindications": {
                "disease": "Probable oral lethal dose reported in humans is above 15 g kg L2695 Ingestion of large quantities may result in abdominal distension intestinal obstruction nausea vomiting and difficulty swallowing Aspiration or inhalation may lead to pneumonitis L2695 In the event of overdosage symptomatic treatment should be given F46",
                "pregnancy": "NA",
                "machine_ops": "NA",
                "pharmacodynamics": "Alginic acid reduces reflux via its floating foaming and viscous properties A27142 Alginic acid precipitates upon contact with gastric acid to create a mechanical barrier or a raft that displaces the postprandial acid pocket A32960 The formation of a raft is thought to occur rapidly often within a few seconds of dosing A32961 In clinical trials alginic acid was effective in reducing the symptoms of gastroesophageal reflux disease GERD A32960 In healthy volunteers alginic acid in combination with an antacid was effective in decreasing postprandial reflux in the upright position A27141 Alginic acid is able to bind to cations when ingested L2695",
                "excipients": "NA",
                "incompatibilities": []
            }
        },
        "revision_date": "2023-05-14"
    }
}